| USGOV-DEPARTMENT-OF-DEFENSE |
USGOV-DEPARTMENT-OF-DEFENSE |
95%
|
USAspending awards from Department of Defense: $428,663 across 10 awards. SPE8E725P0242 8511127216!LIGHT,LIP,SPECIAL; SPE8EG26F0003 8511700996!LIGHT,LIP,SPECIAL; SPE8E725V0394 8511253169!LIGHT,LIP,SP… |
| ONE-CUSTOMER |
ONE-CUSTOMER |
92%
|
Sales to one customer, principally of the VIVID® Pill counter, represented 31% and 23% of the Company's consolidated net revenues for the years ended December 31, 2025 and 2024, respectively. |
| CUSTOMER |
CUSTOMER |
90%
|
For the three months ending March 31, 2025, two customers accounted for approximately 10 % of the Company’s total revenue. |
| ADAM-EQUIPMENT-CO-LTD |
ADAM-EQUIPMENT-CO-LTD |
62%
|
. The Company holds a patent relating to Torbal’s VIVID® automated pill counter which expires in March 2039. The Company’s Bioprocessing Systems operations’ Aquila subsidiary holds three US patents r… |
| A-D-COMPANY-LTD |
A-D-COMPANY-LTD |
62%
|
. The Company holds a patent relating to Torbal’s VIVID® automated pill counter which expires in March 2039. The Company’s Bioprocessing Systems operations’ Aquila subsidiary holds three US patents r… |
| BENCHTOP-LABORATORY-EQUIPMENT-BIOPROCESSING-SYST |
BENCHTOP-LABORATORY-EQUIPMENT-BIOPROCESSING-SYST |
62%
|
,107,300 $ 563,900 $ - $ 3,671,200 Foreign revenue - 1,125,900 - 1,125,900 Total revenue 3,107,300 1,689,800 - 4,797,100 Segment Significant Expenses: Cost of revenues 2,076,700 713,800 - 2,790,500 C… |
| PRESENTATION-SCIENTIFIC-INDUSTRIES-INC |
PRESENTATION-SCIENTIFIC-INDUSTRIES-INC |
62%
|
ency exchange rates on cash and cash equivalents ( 46,800 ) 9,300 Net decrease in cash and cash equivalents ( 157,200 ) ( 117,800 ) Cash and cash equivalents, beginning of period 955,000 587,900 Cash… |
| SCIENTIFIC-BIOPROCESSING-INC |
SCIENTIFIC-BIOPROCESSING-INC |
62%
|
ency exchange rates on cash and cash equivalents ( 46,800 ) 9,300 Net decrease in cash and cash equivalents ( 157,200 ) ( 117,800 ) Cash and cash equivalents, beginning of period 955,000 587,900 Cash… |
| SCIENTIFIC-INDUSTRIES-INC-SCIENTIFIC-BIOPROCESSI |
SCIENTIFIC-INDUSTRIES-INC-SCIENTIFIC-BIOPROCESSI |
62%
|
ency exchange rates on cash and cash equivalents ( 46,800 ) 9,300 Net decrease in cash and cash equivalents ( 157,200 ) ( 117,800 ) Cash and cash equivalents, beginning of period 955,000 587,900 Cash… |
| TROEMNER-LLC |
TROEMNER-LLC |
62%
|
1,227,100 Foreign Sales - 270,300 - 270,300 Loss From Operations ( 197,500 ) ( 1,112,900 ) ( 357,300 ) ( 1,667,700 ) Assets 3,016,000 3,234,500 4,853,000 11,103,500 Long-Lived Asset Expenditures - 6,… |
